The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).

Churchyard, Gavin John; Snowden, Margaret Ann; Hokey, David A.; Dheenadhayalan, Veerabadran; McClain, J. Bruce; Douoguih, Macaya; Pau, Maria Grazia; Sadoff, Jerry; Landry, Bernard

doi:10.1016/j.vaccine.2015.02.004

Record: found
Abstract: found
Article: not found

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).

Author(s): Gavin John Churchyard ¹ , Margaret Ann Snowden ² , David Hokey ² , Veerabadran Dheenadhayalan ² , J Bruce McClain ² , Macaya Douoguih ³ , Maria Grazia Pau ³ , Jerry Sadoff ³ , Bernard Landry ²

Publication date (Electronic): Apr 08 2015

Journal: Vaccine

Publisher: Elsevier BV

Keywords: Clinicaltrials.gov (NHREC no. NCT01017536), DOH-27-0809-2497, HIV, Immunogenicity, Safety, Tuberculosis, Vaccines

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The safety and immunogenicity of a replication deficient adenovirus serotype 35 tuberculosis (TB) vaccine containing gene inserts for Antigens (Ag) 85A, Ag85B and TB10.4 (AERAS-402/AD35.TB-S) was evaluated in previously BCG vaccinated, HIV-infected South African adults with baseline CD4 counts >350 cells/mm(3).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Vaccine

Title: Vaccine

Publisher: Elsevier BV

ISSN (Electronic): 1873-2518

ISSN (Print): 0264-410X

Publication date (Electronic): Apr 08 2015

Volume: 33

Issue: 15

Affiliations

[1 ] Aurum Institute, Johannesburg, South Africa; School of Public Health, University of Witwatersrand, Johannesburg, South Africa. Electronic address: gchurchyard@auruminstitute.org.

[2 ] Aeras, Rockville, MD, United States.

[3 ] Crucell Holland N.V., Leiden, The Netherlands.

Article

Publisher Item ID: S0264-410X(15)00170-X

DOI: 10.1016/j.vaccine.2015.02.004

PubMed ID: 25698492

SO-VID: ce0810c2-5600-4cd1-9edf-8118dd9a17bb

History

Keywords: Clinicaltrials.gov (NHREC no. NCT01017536),DOH-27-0809-2497,HIV,Immunogenicity,Safety,Tuberculosis,Vaccines

Data availability:

Keywords: Clinicaltrials.gov (NHREC no. NCT01017536), DOH-27-0809-2497, HIV, Immunogenicity, Safety, Tuberculosis, Vaccines

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).

Read this article at

Abstract

Related collections

Malaria vaccine development

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 25

Cited by 16